CGRP对氧化损伤人脐静脉内皮细胞的保护作用及Caveolin-1表达的影响  

Effect of CGRP on Protection of Human Umbilical Vein Endothelial Cells and Caveolin-1 Expression Induced by H_2O_2

作　　者：周孝钱[1] 许俊[1] 唐江琼[1] 秦旭平[1] 

机构地区：[1]南华大学药物药理研究所,湖南衡阳421001

出　　处：《中南医学科学杂志》2011年第2期131-134,共4页Medical Science Journal of Central South China

基　　金：国家自然科学基金资助(30572192);南华大学学术带头人培养对象资金资助

摘　　要：目的探讨降钙素基因相关肽（CGRP）对过氧化氢（H2O2）诱导离体培养的人脐静脉内皮细胞（hU-VECs）损伤的保护作用及其机制。方法 CGRP预孵育hUVECs后,用不同浓度H2O2处理hUVECs,噻唑蓝比色法（MTT）观察hUVECs活性;Western-blot检测Caveolin-1表达。结果 CGRP（0.1-100.0 nmol/L）能呈浓度依赖性提高hUVECs活性。H2O2（0.2-5.0 mmol/L）能呈浓度依赖性降低hUVECs活性。CGRP（10~100 nmol/L）预孵育hUVECs 30 min能明显提高H2O2诱导的hUVECs抗损伤能力（P（0.05）;与0.1%FBS组比较,100 nmol/LCGRP和0.05 mmol/L H2O2处理组细胞Caveolin-1蛋白水平表达下降（P（0.05）;0.8 mmol/L H2O2处理组细胞Caveolin-1蛋白表达水平上升（P〈0.05）;与H2O2处理组比较,100 nmol/L CGRP预孵育hUVECs 30 min能显著降低细胞Caveolin-1蛋白水平的表达（P（0.05）。结论 CGRP对H2O2诱导的hUVECs损伤有一定的保护作用,其机制可能与下调氧化应激导致的hUVECs Caveolin-1的表达有关。Objective To study the protective effect of cacitonin gene-related peptide（CGRP） on human umbilical vein endothelial cells（hUVECs） injury induced by H2O2 and the related mechanism of action.Methods CGRP and/or H2O2 were used for treatment of hUVECs.Cell viability was determined by methyl thiazolyltetrazolium（MTT） assay.Expression of Caveolin-1 was measured by Western-blot.Results CGRP（0.1~100.0 nmol/L）could dose-dependently induce the cell viability of hUVECs.H2O2（0.2~5.0 mmol/L）could dose-dependently impaire the cell viability of hUVECs.Pretreatment of hUVECs 30min with CGRP（10~100 nmol/L）dose-dependently increased the cell viability impaired by H2O2.Compared with 0.1%FBS group,100 nmol/L CGRP and 0.05 mol/L H2O2 down-regulated the expression of Caveolin-1,which was up-regulation of incubation of 0.8 mmol/L of H2O2.Compared with H2O2 group,the expression of Caveolin-1 was significantly decreased by pretreatment with CGRP.Conclusion CGRP has a protective effect on the hUVECs injured by H2O2;the mechanism may be related to decreasing the expression of Caveolin-1.

关 键 词：过氧化氢 CGRP CAVEOLIN-1 内皮细胞 动脉粥样硬化 

分 类 号：R541.4[医药卫生—心血管疾病]